Zusammenfassung
Dieses Kapitel strebt einen Kurzüberblick des derzeitigen Verständnisses von der Verbreitung neuer psychoaktiver Substanzen (NPS) auf der Grundlage von Prävalenzschätzungen an. Berichtet werden Ergebnisse aus größeren Umfragen der letzten beiden Jahre (2013–2015). Beschrieben wird außerdem, wie verschiedene allgemeine Umfragen in der Bevölkerung versucht haben, den Gebrauch einzuschätzen. Das Review enthält sowohl große Zufallsstichproben mit Privathaushalten (inklusive sekundärer Analysen) als auch namhafte Forschung auf der Grundlage von Gelegenheitsstichproben. Es werden auch kurze Hinweise auf neue Methoden und Datenquellen des Gesundheitsmonitorings gegeben, die das Verständnis für diese Substanzen verbessern könnten. Zusammenfassend wird klar, dass die Prävalenz von NPS trotz wachsender öffentlicher und politischer Aufmerksamkeit gering bleibt und der Gebrauch einiger bekannter Substanzen sogar abnimmt. Allerdings bleibt das Gebiet methodologisch schwach und während Angaben aus allgemeinen Bevölkerungsstichproben vermutlich eine Unterschätzung des Gebrauchs darstellen, leiden Umfragen in „Hochrisikogruppen“ bezüglich der Wahrscheinlichkeit des Gebrauchs unter zahlreichen Verzerrungen (biases). Es gibt außerdem einen Mangel an Daten über NPS-Gebrauch und den damit verbundenen Verhaltensweisen in Bevölkerungsgruppen, die möglicherweise einen höheren Interventions- und Behandlungsbedarf aufweisen, wie zum Beispiel Personen mit besonderen Bedürfnissen – inklusive problematischem Drogengebrauch –, psychischen Erkrankungen, Obdachlose und jene, die in Kontakt mit dem Strafvollzugssystem sind.
Literatur
American Association of Poison Control. (2015). Synthetic Marijuana Data. http://www.aapcc.org/alerts/synthetic-cannabinoids. Zugegriffen am 09.2015.
Archer, J. R., Hudson, S., Jackson, O., Yamamoto, T., Lovett, C., Lee, H. M., et al. (2015). Analysis of anonymized pooled urine in nine UK cities: Variation in classical recreational drug, novel psychoactive substance and anabolic steroid use. QJM, 108(12), 929–933.
Australian Institute of Health and Welfare. (2014). National Drug Strategy Household Survey detailed report 2013. Drug statistics series. Canberra: Australian Institute of Health and Welfare.
Barratt, M. J., Cakic, V., & Lenton, S. (2013). Patterns of synthetic cannabinoid use in Australia. Drug and Alcohol Review, 32, 141–146.
Barrett, S. P., Meisner, J. R., & Stewart, S. H. (2008). What constitutes prescription drug misuse? Problems and pitfalls of current conceptualizations. Current Drug Abuse Reviews, 1, 255–262.
Centers for Disease Control. (2015). Notes from the field: Increase in reported adverse health effects related to synthetic cannabinoid use – United States, January–May 2015. Morbidity and Mortality Weekly Report, 64, 618–620.
Champion, K. E., Teesson, M., & Newton, N. C. (2015). Patterns and correlates of new psychoactive substance use in a sample of Australian high school students. Drug and Alcohol Review, 35(3), 338–344.
EMCDDA. (2015). Perspectives on drugs: Wastewater analysis and drugs: A European multi-city study. Lisbon: EMCDDA.
European Commission. (2014). Flash Eurobarometer 401 (young people and drugs). Brüssel: European Commission.
Fuller, E. (2015). Smoking, drinking and drug use among young people in England in 2014. London: Health and Social Care Information Centre.
Goggin, L. S., Gately, N., & Bridle, R. I. (2015). Novel psychoactive substance and other drug use by young adults in Western australia. Journal of Psychoactive Drugs, 47, 140–148.
Hawkins, J. D., Catalano, R. F., & Miller, J. Y. (1992). Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: Implications for substance abuse prevention. Psychological Bulletin, 112, 64–105.
Hibell, B. (2014). A test of the EMQ module about New Psychoactive Substances (NPS). EMCDDA annual GPS expert meeting. Lisbon: EMCDDA.
Hibell, B., Guttormsson, U., Ahlstrom, S., Balakireva, O., Bjarnason, T., Kokkevi, A., et al. (2012). The 2011 ESPAD report. Substance use among students in 36 European countries. Stockholm: Swedish Council for Information on Alcohol and Other Drugs (CAN).
Hill, S. L., Doris, T., Gurung, S., Katebe, S., Lomas, A., Dunn, M., et al. (2013). Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: Case series. Clinical Toxicology, 51, 487–492.
Home Office Statistics. (2014). Drug misuse: Findings from the 2013/14 Crime Survey for England and Wales. London: Home Office.
Johnson, T. P. (2014). Sources of error in substance use prevalence surveys. International Scholarly Research Notices, 1–21. doi:10.1155/2014/923290.
Johnson, L. D., O’Malley, P. M., Bachmann, J. G., & Schulenberg, J. E. (2012). Monitoring the future national results on adolescent drug use: Overview of key findings, 2011. Ann Arbor: Institute for Social Research, The University of Michigan.
Kann, L., Kinchen, S., Shanklin, S., Flint, K. H., Hawkins, J., Harris, W. A., et al. (2014). Youth risk behavior surveillance – United Sates, 2013. Morbidity and Mortality Weekly Report, 63(4), 13–24.
Kinyua, J., Covaci, A., Maho, W., McCall, A. K., Neels, H., & van Nujis, A. L. (2015). Sewage-based epidemiology in monitoring the use of new psychoactive substances: Validation and application of an analytical method using LC-MS/MS. Drug Testing and Analysis, 7, 812–818.
Kraus, L., Pabst, A., Gomes de Matos, E., & Piontek, D. (2014). Kurzbericht Epidemiologischer Suchtsurvey 2012. Tabellenband: Prävalenz des Konsums illegaler Drogen, multipler Drogenerfahrung und drogenbezogener Störungen nach Geschlecht und Alter im Jahr 2012. München: Institut für Therapieforschung.
Lader, D. (2015). Drug misuse: Findings from the 2014/15 Crime Survey for England and Wales. London: Home Office.
Lally, J., Higaya, E. E., Nisar, Z., Bainbridge, E., & Hallahan, B. (2013). Prevalence study of head shop drug usage in mental health services. The Psychiatrist, 37, 44–48.
Lawn, W., Barratt, M., Williams, M., Horne, A., & Winstock, A. (2014). The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample. Journal of Psychopharmacology, 28, 780–788.
Lovett, C. J., Measham, F., Dargan, P., & Wood, D. M. (2014). Awareness and use of the NBOMe novel psychoactive substances is lower than those of mephedrone in a high drug using population. Clinical Toxicology, 52, 361.
Martinotti, G., Lupi, M., Carlucci, L., Cinosi, E., Santacroce, R., Acciavatti, T., et al. (2015). Novel psychoactive substances: Use and knowledge among adolescents and young adults in urban and rural areas. Human Psychopharmacology, 30, 295–301.
Miech, R. A., Johnston, L. D., O’Malley, P. M., Bachman, J. G., & Schulenberg, J. E. (2015). Monitoring the future national survey results on drug use, 1975–2014: Volume I, secondary school students. Ann Arbor: Institute for Social Research, The University of Michigan.
Miller, B. L., & Stogner, J. M. (2014). Not-so-clean fun: A profile of bath salt users among a college sample in the United States. Journal of Psychoactive Drugs, 46, 147–153.
Mowry, J. B., Spyker, D. A., Cantilena, L. R., McMillan, N., & Ford, M. (2014). 2013 annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 31st annual report. Clinical Toxicology, 52, 1032–1283.
National Advisory Committe on Drugs (NACD), & Public Health Information and Research Branch (PHIRB). (2011). Drug use in Ireland and Northern Ireland: First results from the 2010/11 drug prevalence survey. Dublin: NACD & PHIRB.
National Poisons Information Service. (2014). National poisons information service report 2013/14. London: Public Health England.
Palamar, J. J. (2015). „Bath salt“ use among a nationally representative sample of high school seniors in the United States. The American Journal on Addictions, 24(6), 488–491.
Palamar, J. J., & Acosta, P. (2015). Synthetic cannabinoid use in a nationally representative sample of US high school seniors. Drug and Alcohol Dependence, 149, 194–202.
Palamar, J. J., Martins, S. S., Su, M. K., & Ompad, D. C. (2015). Self-reported use of novel psychoactive substances in a US nationally representative survey: prevalence, correlates, and a call for new survey methods to prevent underreporting. Drug and Alcohol Dependence, 156, 112–119.
Propel Centre for Population Health. (2014). 2012/13 youth smoking survey: Results profile for Canada. Waterloo: University of Waterloo.
Reid, M. J., Derry, L., & Thomas, K. V. (2014). Analysis of new classes of recreational drugs in sewage: Synthetic cannabinoids and amphetamine-like substances. Drug Testing and Analysis, 6, 72–79.
Rose, S. R., Cumpston, K. L., Stromberg, P. E., & Wills, B. K. (2012). Severe poisoning following self-reported use of 25-I, a novel substituted amphetamine. Clinical Toxicology, 50, 707–708.
Sindicich, N., & Burns, L. (2015). Australian trends in ecstasy and related drug markets 2014. Findings from the Ecstasy and Related Drugs Reporting System (EDRS). Australian drug trends series. Sydney: National Drug and Alcohol Research Centre, UNSW Australia.
Substance Abuse and Mental Health Services Administration. (2013). Drug abuse warning network, 2011: National estimates of drug-related emergency department visits. Rockville: Substance Abuse and Mental Health Services Administration.
Substance Abuse and Mental Health Services Administration. (2014a). Results from the 2013 National Survey on Drug Use and Health: Summary of national findings. Rockville: Substance Abuse and Mental Health Services Administration.
Substance Abuse and Mental Health Services Administration. (2014b). Dawn report september 2014: „Bath Salts“ were involved in over 20,000 drug-related emergency department visits in 2011. Data spotlight. Rockville: Substance Abuse and Mental Health Services Administration.
Substance Abuse and Mental Health Services Administration. (2014c). Update: Drug-related emergency department visits involving synthetic cannabinoids. Rockville: Substance Abuse and Mental Health Services Administration.
Sumnall, H. R., Evans-Brown, M., & McVeigh, J. (2011). Social, policy, and public health perspectives on new psychoactive substances. Drug Testing and Analysis, 3, 515–523.
Sumnall, H. R., Brown, M. E., & McVeigh, J. (2013). Epidemiology of use of novel psychoactive substances. In P. Dargan & D. M. WOOD (Hrsg.), Novel psychoactive substances (S. 79–103). London: Academic Press.
U.S. Department of Justice, U.S. Drug Enforcement Administration, & Office of Diversion Cotrol. (2014). National Forensic Laboratory Information System (NFLIS) special report: Synthetic cannabinoids and synthetic cathinones reported in NFLIS, 2010–2013. Springfield: U.S. Drug Enforcement Administration.
Winstock, A. R. (2015). The global drug survey 2015 findings. Global Drug Survey. http://www.globaldrugsurvey.com/the-global-drug-survey-2015-findings. Zugegriffen am 09.2015.
Wood, D. M., Hill, S. L., Thomas, S. H., & Dargan, P. I. (2014). Using poisons information service data to assess the acute harms associated with novel psychoactive substances. Drug Testing and Analysis, 6, 850–860.
Young, M. M., Dubeau, C., & Corazza, O. (2015). Detecting a signal in the noise: Monitoring the global spread of novel psychoactive substances using media and other open-source information. Human Psychopharmacology, 30, 319–326.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Sumnall, H. (2016). Epidemiologie des Konsums von neuen psychoaktiven Substanzen. In: von Heyden, M., Jungaberle, H., Majić, T. (eds) Handbuch Psychoaktive Substanzen. Springer Reference Psychologie . Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55214-4_94-1
Download citation
DOI: https://doi.org/10.1007/978-3-642-55214-4_94-1
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-55214-4
eBook Packages: Springer Referenz Psychologie